Taro Pharm Inds (TARO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2024 | 03-2023 | 03-2022 | 03-2021 | 03-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 421,856 | 274,475 | 298,720 | 605,177 | 513,354 |
| Marketable Securities | 457,495 | 575,814 | 522,028 | 418,480 | 595,383 |
| Receivables | 219,235 | 259,470 | 306,699 | 266,886 | 270,788 |
| Inventories | 204,817 | 226,669 | 210,439 | 180,292 | 153,073 |
| TOTAL | $1,303,403 | $1,336,428 | $1,337,886 | $1,470,835 | $1,532,598 |
| Non-Current Assets | |||||
| PPE Net | 217,592 | 190,139 | 199,692 | 205,508 | 209,961 |
| Investments And Advances | 457,991 | 404,896 | 435,189 | 557,209 | 459,639 |
| Intangibles | 17,231 | 17,231 | 11,820 | 7,191 | 0 |
| Other Non-Current Assets | 165,852 | 186,819 | 191,775 | 166,130 | 139,054 |
| TOTAL | $858,666 | $799,085 | $838,476 | $936,038 | $808,654 |
| Total Assets | $2,162,069 | $2,135,513 | $2,176,362 | $2,406,873 | $2,341,252 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 44,664 | 68,484 | 68,232 | 61,166 | 28,858 |
| Accrued Expenses | N/A | 80,019 | 68,739 | N/A | N/A |
| Other current liabilities | 316,443 | 237,045 | 295,147 | 615,135 | 193,873 |
| TOTAL | $361,107 | $385,548 | $432,118 | $676,301 | $222,731 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 19,106 | 32,799 | 47,295 | 5,058 |
| TOTAL | $7,956 | $19,106 | $32,799 | $35,115 | $8,762 |
| Total Liabilities | $369,063 | $404,654 | $464,917 | $711,416 | $231,493 |
| Shareholders' Equity | |||||
| Common Shares | N/A | 679 | 679 | 679 | 679 |
| Retained earnings | N/A | 2,414,136 | 2,388,691 | 2,338,617 | 2,725,270 |
| Other shareholders' equity | 1,793,006 | -175,401 | -169,370 | -160,284 | -157,635 |
| TOTAL | $1,793,006 | $1,730,859 | $1,711,445 | $1,695,457 | $2,109,759 |
| Total Liabilities And Equity | $2,162,069 | $2,135,513 | $2,176,362 | $2,406,873 | $2,341,252 |